Divisadero Street Capital Management LP Decreases Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Divisadero Street Capital Management LP decreased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 56.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 33,229 shares of the company’s stock after selling 42,707 shares during the quarter. Divisadero Street Capital Management LP owned about 0.10% of TransMedics Group worth $5,005,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Fidelis Capital Partners LLC bought a new stake in TransMedics Group in the first quarter worth $35,000. International Assets Investment Management LLC bought a new stake in shares of TransMedics Group in the 2nd quarter worth about $47,000. J.Safra Asset Management Corp lifted its holdings in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after acquiring an additional 383 shares during the last quarter. Signaturefd LLC boosted its stake in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the period. Finally, Amalgamated Bank grew its holdings in TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after purchasing an additional 70 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on TMDX shares. Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Piper Sandler increased their price target on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. TD Cowen boosted their price objective on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Morgan Stanley upped their price objective on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Finally, Needham & Company LLC assumed coverage on TransMedics Group in a research report on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price for the company. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $171.44.

TransMedics Group Price Performance

TMDX opened at $165.98 on Friday. The company has a market capitalization of $5.47 billion, a price-to-earnings ratio of -488.18 and a beta of 1.99. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $177.37. The business’s fifty day simple moving average is $155.19 and its 200-day simple moving average is $128.44.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. During the same period in the prior year, the business earned ($0.03) EPS. The firm’s quarterly revenue was up 117.7% on a year-over-year basis. On average, equities research analysts anticipate that TransMedics Group, Inc. will post 1.23 earnings per share for the current fiscal year.

Insider Activity

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at $3,267,557.11. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at $3,267,557.11. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,247 shares of company stock worth $9,650,880. Corporate insiders own 7.00% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.